Celgene Loses Sanctions Bid Against Teva Unit In Patent Row
A Florida federal judge on Wednesday denied Celgene Corp.'s bid to sanction a Teva Pharmaceutical Industries Ltd. unit for pursuing a patent infringement case involving Celgene's bone-marrow cancer drug Vidaza that...To view the full article, register now.
Already a subscriber? Click here to view full article